BACKGROUND: Pharmacogenetics of tardive dyskinesia and dopamine D3 (DRD3), serotonin 2A (HTR2A), and 2C (HTR2C) receptors has been examined in various populations, but not in Russians. PURPOSE: To investigate the association between orofaciolingual (TDof) and limb-truncal dyskinesias (TDlt) and Ser9Gly (DRD3), -1438G>A (HTR2A), and Cys23Ser (HTR2C) polymorphisms in Russian psychiatric inpatients from Tomsk, Siberia. METHODS: In total, 146 subjects were included. Standard protocols were applied for genotyping. TDof and TDlt were assessed with AIMS items 1-4 and 5-7, respectively. Two-part model, logistic and log-normal regression analyses were applied to assess different variables (e.g., allele-carriership status, age, gender, and medication use). RESULTS: TDlt, but not TDof, exhibited an association with Ser9Gly and Cys23Ser (with 9Gly and 23Ser alleles exhibiting opposite effects). However, -1438G>A was not associated with TDof and Dlt. CONCLUSIONS: This is the first pharmacogenetic report on tardive dyskinesia in Russians. Subject to further replication, our findings extend and support the available data.
BACKGROUND: Pharmacogenetics of tardive dyskinesia and dopamine D3 (DRD3), serotonin 2A (HTR2A), and 2C (HTR2C) receptors has been examined in various populations, but not in Russians. PURPOSE: To investigate the association between orofaciolingual (TDof) and limb-truncal dyskinesias (TDlt) and Ser9Gly (DRD3), -1438G>A (HTR2A), and Cys23Ser (HTR2C) polymorphisms in Russian psychiatric inpatients from Tomsk, Siberia. METHODS: In total, 146 subjects were included. Standard protocols were applied for genotyping. TDof and TDlt were assessed with AIMS items 1-4 and 5-7, respectively. Two-part model, logistic and log-normal regression analyses were applied to assess different variables (e.g., allele-carriership status, age, gender, and medication use). RESULTS: TDlt, but not TDof, exhibited an association with Ser9Gly and Cys23Ser (with 9Gly and 23Ser alleles exhibiting opposite effects). However, -1438G>A was not associated with TDof and Dlt. CONCLUSIONS: This is the first pharmacogenetic report on tardive dyskinesia in Russians. Subject to further replication, our findings extend and support the available data.
Authors: Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis Journal: Curr Pharmacogenomics Person Med Date: 2011-06-01
Authors: Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder Journal: Psychopharmacology (Berl) Date: 2011-07-13 Impact factor: 4.530
Authors: Olga Yu Fedorenko; Anton J M Loonen; Florian Lang; Valentina A Toshchakova; Evgenia G Boyarko; Arkadiy V Semke; Nikolay A Bokhan; Nikolay V Govorin; Lyubomir I Aftanas; Svetlana A Ivanova Journal: Int J Neuropsychopharmacol Date: 2014-12-28 Impact factor: 5.176
Authors: P Roberto Bakker; Asmar F Y Al Hadithy; Najaf Amin; Cornelia M van Duijn; Jim van Os; Peter N van Harten Journal: PLoS One Date: 2012-12-04 Impact factor: 3.240
Authors: Svetlana A Ivanova; Anton Jm Loonen; P Roberto Bakker; Maxim B Freidin; Nienke J Ter Woerds; Asmar Fy Al Hadithy; Arkadiy V Semke; Olga Yu Fedorenko; Jacobus Rbj Brouwers; Nikolay A Bokhan; Jim van Os; Peter N van Harten; Bob Wilffert Journal: SAGE Open Med Date: 2016-04-11